Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 1

EGFR mNSCLC: Treatment Overview and Challenges

,

Panelists discuss how EGFR tyrosine kinase inhibitors (TKIs) have revolutionized first-line treatment for EGFR-positive non–small cell lung cancer (NSCLC).

Now Viewing
EP. 1: EGFR mNSCLC: Treatment Overview and Challenges
EP. 2: FLAURA and FLAURA2: Key Efficacy and Safety Data

Video content above is prompted by the following:

  • Provide a brief overview of the treatment landscape of first-line treatment for patients with EGFR-positive NSCLC.